Morningstar brands and products Company Portfolio ...

Coeptis Therapeutics (COEP) announced the expansion of its license agreement with Deverra Therapeutics, broadening the potential applications of its allogeneic natural killer cell technology.

GeekWire’s startup coverage documents the Pacific Northwest entrepreneurial scene. Sign up for our weekly startup newsletter, and check out the GeekWire funding tracker and venture capital ...

(RTTNews) - Coeptis Therapeutics Holdings, Inc. (COEP) has entered into a binding term sheet with Deverra Therapeutics, Inc. pursuant to which it has obtained an exclusive right, until August 31 ...

Under the transaction, Coeptis paid to Deverra approximately $570,000 in cash and issued to Deverra 4,000,000 shares of Coeptis' common stock. About Coeptis Therapeutics Holdings, Inc. Deverra ...

SEATTLE, WA / ACCESSWIRE / March 19, 2024 / Deverra Therapeutics Inc., a clinical-stage biotechnology company developing allogeneic universal donor cell therapy treatments to fight cancer and ...

Coeptis Therapeutics Holdings, Inc., a biopharmaceutical company developing innovative cell therapy platforms for cancer, announced that Deverra Therapeutics, Inc. (Deverra Therapeutics) was selected ...

Deverra Therapeutics Inc., a clinical-stage company in Seattle, has entered into a manufacturing service agreement with the Cleveland Cell Therapy Incubator (CCTI) to manufacture the clinical-grade ...

WEXFORD, Pa., Oct. 24, 2024 /PRNewswire/ -- Coeptis Therapeutics Holdings, Inc. (Nasdaq: COEP) (the "Company" or "Coeptis"), a biopharmaceutical company developing ...

In August 2023, Coeptis secured its exclusive license to key assets from Deverra, including an allogeneic stem cell expansion and directed differentiation platform, two investigational new drug (IND) ...